Investigation the effect of trehalose on ALS
Not Applicable
Not yet recruiting
- Conditions
- Amiytrophic Lateral Sclerosis (ALS).Motor neuron diseaseG12.2
- Registration Number
- IRCT20181022041407N6
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Patient with ALS diagnosis (according to Gold Coast criteria)
Obtaining the score of 0, 1, or 2 in each ALS-FRS item
Satisfaction for participation in the research project
Exclusion Criteria
Uncontrolled and severe adverse event
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie trehalose's potential therapeutic effects in ALS patients?
How does trehalose compare to standard-of-care treatments like riluzole and edaravone in ALS management?
Are there specific biomarkers that can predict ALS patient response to trehalose therapy?
What are the known adverse events associated with trehalose administration in neurodegenerative diseases?
What combination therapies or competitor drugs show promise in targeting motor neuron degeneration in ALS?